EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische StudieVergleichsstudieOpen Access · CC BY 4.0

Comparative Effectiveness of Switching From First‐Generation Basal Insulins to Either Glargine 300 U/mL or Degludec 100 U/mL in Children and Adolescents With Type 1 Diabetes: Results From the ISPED CARD Clinical Registry

Ivana Rabbone iD, Riccardo Bonfanti iD, Giusi Graziano iD, Fortunato Lombardo iD, Antonio Nicolucci iD, Marco Marigliano iD, Maria Chiara Rossi iD, Giacomo Vespasiani iD, Valentino Cherubini iD

Pediatric Diabetes · 2025

DOI: 10.1155/pedi/5514402 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Pediatric Diabetes, 2025. Verfasst von Ivana Rabbone und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatrics, Department of Health Sciences, Università del Piemonte Orientale, Novara, Italy. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Insulin Glargine, Insulin, Long-Acting, Hypoglycemic Agents. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

To assess the real‐world effectiveness of switching from first‐generation basal insulins (1BIs) to either glargine U300 (Gla‐300) or degludec U100 (Deg‐100) in children and adolescents with type 1 diabetes (T1D), using data from the Italian ISPED CARD clinical registry. Materials and Methods This multicenter retrospective observational study included 1063 pediatric patients with T1D from 22 diabetes centers across Italy who switched from 1BI to either Gla‐300 (64.6%) or Deg‐100 (35.4%) between 2021 and 2023. Propensity score matching (PSM) was applied to create comparable groups ( n = 353 per group). Primary endpoint was the change in HbA1c at 6 months. Secondary endpoints included fasting blood glucose (FBG), standardized body mass index (BMI/SDS), and insulin doses at 6 and 12 months. Longitudinal models for repeated measures were used to assess treatment effectiveness.

Results

Both groups showed significant and clinically relevant reductions in HbA1c at 6 months from ~ 8.7% to ~ 7.4% (−1.3 percentage points), maintained at 12 months, with no significant differences between groups. FBG also decreased significantly in both groups, slightly favoring Deg‐100, but without statistical significance between groups. BMI/SDS remained stable. Gla‐300 was associated with a slight increase in basal insulin dose over 12 months, while Deg‐100 showed a temporary reduction at 6 months. A significant reduction in short‐acting insulin dose (−0.03 U/kg) was observed in both groups.

Conclusion

Switching from 1BI to either Gla‐300 or Deg‐100 significantly improves glycemic control in pediatric T1D patients without weight gain. Although both insulins showed comparable effectiveness, differences in titration patterns highlight the need for individualized treatment strategies and improved clinician education in insulin optimization. Safety outcomes, particularly hypoglycemia, could not be assessed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 1Insulin GlargineInsulin, Long-ActingHypoglycemic AgentsDrug SubstitutionHumansAdolescentChildMaleFemaleRetrospective StudiesRegistriesGlycated HemoglobinBlood GlucoseTreatment OutcomeItaly

Stichwörter der Autor:innen

basal insulin analoguesclinical registrydegludec 100 U/mLglargine 300 U/mLpediatric diabetesreal-world evidencetype 1 diabetes

Substanzen

Insulin GlargineInsulin, Long-ActingHypoglycemic Agentsinsulin degludecGlycated HemoglobinBlood Glucosehemoglobin A1c protein, human

Autor:innen und Institutionen

  • Division of Pediatrics, Department of Health Sciences, Università del Piemonte Orientale, Novara, Italy.
  • Department of Pediatrics, Pediatric Diabetology Unit, Diabetes Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy.
  • CORESEARCH - Center for Outcomes Research and Clinical Epidemiology, Pescara, Italy.
  • Department of Human Pathology in Adult and Developmental Age "Gaetano Barresi", University of Messina, Messina, Italy.
  • Department of Surgery, Dentistry, Pediatrics and Gynecology, Section of Pediatric Diabetes and Metabolism, University of Verona, Verona, Italy.
  • Meteda Srl, San Benedetto del Tronto (AP), Italy.

ORCID-Profile: Ivana Rabbone, Riccardo Bonfanti, Giusi Graziano, Fortunato Lombardo, Antonio Nicolucci, Marco Marigliano, Maria Chiara Rossi, Giacomo Vespasiani, Valentino Cherubini

Zitieren

APA

Rabbone, I., Bonfanti, R., Graziano, G., Lombardo, F., Nicolucci, A., Marigliano, M., Rossi, M. C., Vespasiani, G., & Cherubini, V. (2025). Comparative Effectiveness of Switching From First‐Generation Basal Insulins to Either Glargine 300 U/mL or Degludec 100 U/mL in Children and Adolescents With Type 1 Diabetes: Results From the ISPED CARD Clinical Registry. Pediatric Diabetes. https://doi.org/10.1155/pedi/5514402

Vancouver

Rabbone I, Bonfanti R, Graziano G, Lombardo F, Nicolucci A, Marigliano M, et al. Comparative Effectiveness of Switching From First‐Generation Basal Insulins to Either Glargine 300 U/mL or Degludec 100 U/mL in Children and Adolescents With Type 1 Diabetes: Results From the ISPED CARD Clinical Registry. Pediatric Diabetes. 2025. doi:10.1155/pedi/5514402

BibTeX
@article{Rabbone2025,
  author = {Rabbone, Ivana and Bonfanti, Riccardo and Graziano, Giusi and Lombardo, Fortunato and Nicolucci, Antonio and Marigliano, Marco and Rossi, Maria Chiara and Vespasiani, Giacomo and Cherubini, Valentino},
  title = {Comparative Effectiveness of Switching From First‐Generation Basal Insulins to Either Glargine 300 U/mL or Degludec 100 U/mL in Children and Adolescents With Type 1 Diabetes: Results From the ISPED CARD Clinical Registry},
  journal = {Pediatric Diabetes},
  year = {2025},
  doi = {10.1155/pedi/5514402}
}
Kostenlos starten →